Amgen Stock Fluctuates Amid Strong Earnings and Pipeline Concerns

Amgen Inc., a global biotechnology company, has seen its stock price fluctuate due to various factors. In the second quarter, Teamwork Financial Advisors LLC decreased its stake in Amgen by 89.8%, selling 8,835 shares during the period. The firm now owns 1,000 shares of Amgen's stock, valued at $362,000. Meanwhile, other institutional investors have modified their holdings in Amgen, with High Note Wealth LLC growing its stake by 5.8% and TAGStone Capital Inc. lifting its holdings by 0.7%.

Amgen reported second-quarter revenue of approximately $10.05 billion, up 9.5% year over year, while adjusted earnings of $6.29 per share surpassed the $5.62 consensus estimate. The company's guidance was also raised, with management now expecting fiscal-year earnings of $22.30 to $23.50 per share. Analysts have set new price targets for Amgen, with BMO Capital Markets raising its target to $450.

Despite strong results, analyst sentiment remains mixed. Some analysts, such as Wells Fargo and Canaccord Genuity, have raised their targets, while others, like Citi, maintain a Hold rating. The company's pipeline disappointment has also limited the upside case, with Amgen dropping its obesity-drug candidate AMG 513.